Is Ovid Therapeutics Stock a Good Investment?
Ovid Therapeutics Investment Advice | OVID |
- Examine Ovid Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ovid Therapeutics' leadership team and their track record. Good management can help Ovid Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ovid Therapeutics' business and its evolving consumer preferences.
- Compare Ovid Therapeutics' performance and market position to its competitors. Analyze how Ovid Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Ovid Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ovid Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ovid Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ovid Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Ovid Therapeutics Stock
Researching Ovid Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ovid Therapeutics recorded a loss per share of 0.46. The entity had not issued any dividends in recent years.
To determine if Ovid Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ovid Therapeutics' research are outlined below:
| Ovid Therapeutics generated a negative expected return over the last 90 days | |
| Ovid Therapeutics has some characteristics of a very speculative penny stock | |
| Ovid Therapeutics has high historical volatility and very poor performance | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 391.69 K. Net Loss for the year was (52.34 M) with profit before overhead, payroll, taxes, and interest of 1.5 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (45.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Biotechnology Value Fund L Ps Strategic Reduction in Ovid Therapeutics Inc |
Ovid Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ovid Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ovid Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ovid Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ovid Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-04 | 2023-06-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2023-05-05 | 2023-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2023-03-13 | 2022-12-31 | -0.18 | -0.16 | 0.02 | 11 | ||
2023-11-03 | 2023-09-30 | -0.19 | -0.16 | 0.03 | 15 | ||
2022-11-08 | 2022-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2022-08-09 | 2022-06-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2020-05-07 | 2020-03-31 | -0.33 | -0.37 | -0.04 | 12 | ||
2024-05-14 | 2024-03-31 | -0.22 | -0.17 | 0.05 | 22 |
Know Ovid Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ovid Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ovid Therapeutics backward and forwards among themselves. Ovid Therapeutics' institutional investor refers to the entity that pools money to purchase Ovid Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosight Management, Lp | 2024-06-30 | 1.1 M | Tls Advisors Llc | 2024-09-30 | 771.5 K | Wells Fargo & Co | 2024-06-30 | 741.6 K | Ubs O'connor Llc | 2024-09-30 | 628.3 K | Northern Trust Corp | 2024-09-30 | 480.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 309.5 K | Gsa Capital Partners Llp | 2024-09-30 | 260.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 218.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 161.8 K | Rubric Capital Management Lp | 2024-06-30 | 5.3 M | Madison Avenue Partners, Lp | 2024-06-30 | 4.1 M |
Ovid Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.11 M.Market Cap |
|
Ovid Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.60) | (0.63) |
Determining Ovid Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Ovid Therapeutics is a good buy. For example, gross profit margin measures Ovid Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ovid Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Ovid Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.
Evaluate Ovid Therapeutics' management efficiency
Ovid Therapeutics has return on total asset (ROA) of (0.3604) % which means that it has lost $0.3604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3661) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Ovid Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.24 | 2.33 | |
| Tangible Book Value Per Share | 1.24 | 2.32 | |
| Enterprise Value Over EBITDA | (3.68) | (3.87) | |
| Price Book Value Ratio | 2.59 | 3.82 | |
| Enterprise Value Multiple | (3.68) | (3.87) | |
| Price Fair Value | 2.59 | 3.82 | |
| Enterprise Value | 216.2 M | 108.5 M |
The operational strategies employed by Ovid Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.41 |
Basic technical analysis of Ovid Stock
As of the 26th of November, Ovid Therapeutics holds the Coefficient Of Variation of (5,756), risk adjusted performance of (0.01), and Variance of 15.4. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ovid Therapeutics, as well as the relationship between them. Please check Ovid Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Ovid Therapeutics is priced some-what accurately, providing market reflects its current price of 1.09 per share. Given that Ovid Therapeutics is a hitting penny stock territory we advise to closely look at its jensen alpha.Ovid Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ovid Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ovid Therapeutics' Outstanding Corporate Bonds
Ovid Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ovid Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ovid bonds can be classified according to their maturity, which is the date when Ovid Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Ovid Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ovid Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 2.9 | |||
| Coefficient Of Variation | (5,756) | |||
| Standard Deviation | 3.92 | |||
| Variance | 15.4 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.69) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 19.2 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.93 | |||
| Skewness | (0.05) | |||
| Kurtosis | 0.5314 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 2.9 | |||
| Coefficient Of Variation | (5,756) | |||
| Standard Deviation | 3.92 | |||
| Variance | 15.4 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.69) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 19.2 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.93 | |||
| Skewness | (0.05) | |||
| Kurtosis | 0.5314 |
Consider Ovid Therapeutics' intraday indicators
Ovid Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ovid Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2191.47 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1.09 | |||
| Day Typical Price | 1.09 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
Ovid Stock media impact
Far too much social signal, news, headlines, and media speculation about Ovid Therapeutics that are available to investors today. That information is available publicly through Ovid media outlets and privately through word of mouth or via Ovid internal channels. However, regardless of the origin, that massive amount of Ovid data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ovid Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ovid Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ovid Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ovid Therapeutics alpha.
Ovid Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ovid Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ovid Therapeutics Corporate Management
| Meg Alexander | Chief Officer | Profile | |
| Claude MD | Head RD | Profile | |
| SPHR SHRMSCP | VP Facilities | Profile | |
| Jason MBA | Chief Officer | Profile | |
| Lora Pike | Senior Relations | Profile | |
| Garret Bonney | Investor Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ovid Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.